Colin Paul Mendelsohn
Research Subjects
Colin Paul Mendelsohn has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Wayne Hall
National Centre for Youth Substance Use Research University of Queensland Brisbane Australia
8 shared publications- Wayne Hall
The National Centre for Youth Substance Use Research, School of Psychology The University of Queensland Brisbane Australia
6 shared publications Alex Wodak
Alcohol and Drug Service, St Vincents' Hospital Sydney Australia
5 shared publicationsRon Borland
School of Psychology Deakin University ‐ Melbourne Burwood Campus Burwood Australia
4 shared publications- Alex Wodak
St Vincents' Hospital, Alcohol and Drug Service, Darlinghurst Sydney Australia
3 shared publications Robert Beaglehole
Faculty of Medical and Health Sciences The University of Auckland Auckland New Zealand
3 shared publications
Latest Publications
- 1 August 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (8) , 1085-1094
Vaporized Nicotine Products for Smoking Cessation Among People Experiencing Social Disadvantage
Vaporized nicotine products (VNPs) are more effective than nicotine replacement therapy (NRT) for smoking cessation in general populations, but their effectiveness among low socioeconomic groups is largely unknown. To examine whether VNPs are more effective than NRT for smoking cessation among people experiencing social disadvantage. Two-group, open-label, randomized trial with blinded outcome ascertainment. (Australian New Zealand Clinical Trials Registry ACTRN12621000076875). Australia, between March 2021 and December 2022. 1045 adults who smoked daily, were willing to quit smoking, and were receiving a government pension/allowance (proxy for social disadvantage). Participants were randomly assigned (1:1) to either a free 8-week supply of NRT or VNPs, and all participants received text-message support. The primary outcome was 6-month continuous smoking abstinence verified using a carbon monoxide breath test at 7-month follow-up. Analysis included randomly assigned participants in accordance with Russell Standard criteria and the intention-to-treat principle. Among 1045 randomly assigned participants, 866 (82.9%) completed final follow-up. The verified 6-month continuous abstinence rate was 9.6% (50 of 523) in the NRT group and 28.4% (148 of 522) in the VNP group (posterior risk difference estimate, 18.7% [95% credible interval, 14.1% to 23.3%]; >99% posterior probability that VNP is superior). Self-reported adverse events occurred less frequently in the VNP group (355 events among 237 participants) compared with the NRT group (442 events among 278 participants; incident rate ratio, 0.75 [95% CI, 0.65 to 0.88]; P < 0.001). Biochemical verification method tested short-term exposure to cigarette smoke. Findings indicate that VNPs were more effective than NRT for smoking cessation in this population. Given the challenges for cessation among these socially disadvantaged populations, VNPs present a promising treatment option for this priority group. Australian National Health and Medical Research Council.
- 1 August 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (8) , 1085-1094
Vaporized Nicotine Products for Smoking Cessation Among People Experiencing Social Disadvantage
Vaporized nicotine products (VNPs) are more effective than nicotine replacement therapy (NRT) for smoking cessation in general populations, but their effectiveness among low socioeconomic groups is largely unknown. To examine whether VNPs are more effective than NRT for smoking cessation among people experiencing social disadvantage. Two-group, open-label, randomized trial with blinded outcome ascertainment. (Australian New Zealand Clinical Trials Registry ACTRN12621000076875). Australia, between March 2021 and December 2022. 1045 adults who smoked daily, were willing to quit smoking, and were receiving a government pension/allowance (proxy for social disadvantage). Participants were randomly assigned (1:1) to either a free 8-week supply of NRT or VNPs, and all participants received text-message support. The primary outcome was 6-month continuous smoking abstinence verified using a carbon monoxide breath test at 7-month follow-up. Analysis included randomly assigned participants in accordance with Russell Standard criteria and the intention-to-treat principle. Among 1045 randomly assigned participants, 866 (82.9%) completed final follow-up. The verified 6-month continuous abstinence rate was 9.6% (50 of 523) in the NRT group and 28.4% (148 of 522) in the VNP group (posterior risk difference estimate, 18.7% [95% credible interval, 14.1% to 23.3%]; >99% posterior probability that VNP is superior). Self-reported adverse events occurred less frequently in the VNP group (355 events among 237 participants) compared with the NRT group (442 events among 278 participants; incident rate ratio, 0.75 [95% CI, 0.65 to 0.88]; P < 0.001). Biochemical verification method tested short-term exposure to cigarette smoke. Findings indicate that VNPs were more effective than NRT for smoking cessation in this population. Given the challenges for cessation among these socially disadvantaged populations, VNPs present a promising treatment option for this priority group. Australian National Health and Medical Research Council.
Do the differing vaping and smoking trends in Australia and New Zealand reflect different regulatory policies?
Background and Aims: Comparing regulatory models for nicotine vaping products in different countries can provide insights into the most effective regulatory approach but can be confounded by cross‐national differences. This study compared two neighbouring countries with very different vaping regulatory models but with similar tobacco control policies and population demographics. Australia has a highly restrictive, prescription‐only vaping policy, while New Zealand adopted a regulated consumer model.Methods: This study compared trends in daily smoking and vaping among adults and youth from 2016 to 2023 in Australia (adults ≥14 years and ≥15 years; youth 12–17 years) and New Zealand (adults ≥15 years, youth 14–15 years), using published statistics from large nationally representative surveys.Results: Between 2016 and 2023, the decrease in adult daily smoking in New Zealand (from 14.5% to 6.8%) was larger than in Australia (from 12.2% to 8.3%) by a factor of 0.67 [95% confidence interval (CI) = 0.43, 0.93]. However, the increase in adult vaping in New Zealand (from 0.9% to 9.7%) was larger than in Australia (0.5% to 3.5%) by a factor of 0.56 (95% CI = 0.17, 1.02). The largest smoking reductions in both countries were in young adults, who also reported the highest vaping rates. There was a more rapid decline in smoking in the lower socioeconomic groups and Indigenous people in New Zealand than in Australia. Youth smoking rates declined in both countries to very low levels. Youth vaping rates in New Zealand were higher but have started to decline since regulations were introduced.Conclusions: If the association is causal, New Zealand's less restrictive approach to vaping (compared with Australia's more restrictive approach) may have contributed to a more rapid decline in adult smoking, and reduced social inequalities and Indigenous smoking, but at the possible expense of increased youth vaping.
Do the differing vaping and smoking trends in Australia and New Zealand reflect different regulatory policies?
Background and Aims: Comparing regulatory models for nicotine vaping products in different countries can provide insights into the most effective regulatory approach but can be confounded by cross‐national differences. This study compared two neighbouring countries with very different vaping regulatory models but with similar tobacco control policies and population demographics. Australia has a highly restrictive, prescription‐only vaping policy, while New Zealand adopted a regulated consumer model.Methods: This study compared trends in daily smoking and vaping among adults and youth from 2016 to 2023 in Australia (adults ≥14 years and ≥15 years; youth 12–17 years) and New Zealand (adults ≥15 years, youth 14–15 years), using published statistics from large nationally representative surveys.Results: Between 2016 and 2023, the decrease in adult daily smoking in New Zealand (from 14.5% to 6.8%) was larger than in Australia (from 12.2% to 8.3%) by a factor of 0.67 [95% confidence interval (CI) = 0.43, 0.93]. However, the increase in adult vaping in New Zealand (from 0.9% to 9.7%) was larger than in Australia (0.5% to 3.5%) by a factor of 0.56 (95% CI = 0.17, 1.02). The largest smoking reductions in both countries were in young adults, who also reported the highest vaping rates. There was a more rapid decline in smoking in the lower socioeconomic groups and Indigenous people in New Zealand than in Australia. Youth smoking rates declined in both countries to very low levels. Youth vaping rates in New Zealand were higher but have started to decline since regulations were introduced.Conclusions: If the association is causal, New Zealand's less restrictive approach to vaping (compared with Australia's more restrictive approach) may have contributed to a more rapid decline in adult smoking, and reduced social inequalities and Indigenous smoking, but at the possible expense of increased youth vaping.
- 30 May 2023
- Published by Elsevier in International Journal of Drug Policy
- Vol. 117, 104064
What are the harms of vaping in young people who have never smoked?
- 30 May 2023
- Published by Elsevier in International Journal of Drug Policy
- Vol. 117, 104064
What are the harms of vaping in young people who have never smoked?
- 9 May 2023
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (5) , 1301-1302
Response to commentaries on proposed regulation of nicotine vaping
- 9 May 2023
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (5) , 1301-1302
Response to commentaries on proposed regulation of nicotine vaping
- 18 April 2023
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (5) , 1288-1294
How should nicotine vaping be regulated in Australia?
In Australia, nicotine vaping products are regulated as prescription‐only medicines which can only be sold from a pharmacy, with the aim of preventing youth access and allowing use by adult smokers with a doctor's support. The Therapeutic Goods Administration has acknowledged that this policy has not achieved its goals. Instead, a thriving black market has developed which sells unregulated vape products to children and adults. Very few adult vapers use the legal prescription pathway. Regulation should find the optimal balance between facilitating legal access for adult smokers while restricting access by youth. The preferred approach is a tightly regulated consumer model with nicotine vaping products sold by licenced retail outlets with strict age‐of‐sale verification. Regulations should be proportionate to risk and reflect the lower harms of vaping relative to smoking. A consumer model would bring Australia into line with other Western countries and improve population health.
- 18 April 2023
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (5) , 1288-1294
How should nicotine vaping be regulated in Australia?
In Australia, nicotine vaping products are regulated as prescription‐only medicines which can only be sold from a pharmacy, with the aim of preventing youth access and allowing use by adult smokers with a doctor's support. The Therapeutic Goods Administration has acknowledged that this policy has not achieved its goals. Instead, a thriving black market has developed which sells unregulated vape products to children and adults. Very few adult vapers use the legal prescription pathway. Regulation should find the optimal balance between facilitating legal access for adult smokers while restricting access by youth. The preferred approach is a tightly regulated consumer model with nicotine vaping products sold by licenced retail outlets with strict age‐of‐sale verification. Regulations should be proportionate to risk and reflect the lower harms of vaping relative to smoking. A consumer model would bring Australia into line with other Western countries and improve population health.
- Open Access
A critique of the Australian National Health and Medical Research Council CEO statement on electronic cigarettes
This paper critically analyses a statement by Australia's National Health and Medical Research Council (NHMRC) on e‐cigarettes in May 2022 that will be used to guide national policy. We reviewed the evidence and the conclusions drawn in the NHMRC Statement. In our view, the Statement is not a balanced reflection of the benefits and risks of vaping because it exaggerates the risks of vaping and fails to compare them to the far greater risks of smoking; it uncritically accepts evidence of harms from e‐cigarettes while adopting a highly sceptical attitude towards evidence of their benefits; it incorrectly claims that the association between adolescent vaping and subsequent smoking is causal; and it understates the evidence of the benefits of e‐cigarettes in assisting smokers to quit. The Statement dismisses the evidence that vaping is probably already having a positive net public health effect and misapplies the precautionary principle. Several sources of evidence supporting our assessment were published after the NHMRC Statement's publication and are also referenced. The NHMRC Statement on e‐cigarettes does not present a balanced assessment of the available scientific literature and fails to meet the standard expected of a leading national scientific body.
Open AccessA critique of the Australian National Health and Medical Research Council CEO statement on electronic cigarettes
This paper critically analyses a statement by Australia's National Health and Medical Research Council (NHMRC) on e‐cigarettes in May 2022 that will be used to guide national policy. We reviewed the evidence and the conclusions drawn in the NHMRC Statement. In our view, the Statement is not a balanced reflection of the benefits and risks of vaping because it exaggerates the risks of vaping and fails to compare them to the far greater risks of smoking; it uncritically accepts evidence of harms from e‐cigarettes while adopting a highly sceptical attitude towards evidence of their benefits; it incorrectly claims that the association between adolescent vaping and subsequent smoking is causal; and it understates the evidence of the benefits of e‐cigarettes in assisting smokers to quit. The Statement dismisses the evidence that vaping is probably already having a positive net public health effect and misapplies the precautionary principle. Several sources of evidence supporting our assessment were published after the NHMRC Statement's publication and are also referenced. The NHMRC Statement on e‐cigarettes does not present a balanced assessment of the available scientific literature and fails to meet the standard expected of a leading national scientific body.
- 21 December 2022
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 57 (3) , 456-457
Letter to the Editor regarding ‘Smoke and mirrors: Support from psychiatrists for nicotine e-cigarette availability in Australia’
- 21 December 2022
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 57 (3) , 456-457
Letter to the Editor regarding ‘Smoke and mirrors: Support from psychiatrists for nicotine e-cigarette availability in Australia’
- 23 October 2022
- Published by Wiley in Medical Journal of Australia
- Vol. 217 (10) , 547
What doctors should consider before prescribing e‐liquids for e‐cigarettes
- 23 October 2022
- Published by Wiley in Medical Journal of Australia
- Vol. 217 (10) , 547
What doctors should consider before prescribing e‐liquids for e‐cigarettes
- 23 August 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (2) , 258-261
Nicotine vaping was not the cause of e‐cigarette, or vaping, product use‐associated lung injury in the United States
- 23 August 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (2) , 258-261
Nicotine vaping was not the cause of e‐cigarette, or vaping, product use‐associated lung injury in the United States